COL1A1 and steatosis: The initial study reported here was to determine the level of inhibition of disease progression over 8 days with a single dose (1 μM) based on the validated panel of metrics, including steatosis, pro-inflammatory cytokine secretion, and early fibrosis (stellate cell activation and secretion of COL1A1).